Berger Montague Begins Investigation into Akero Therapeutics for Possible Breaches of Duty Berger Montague is investigating Akero Therapeutics and its board for potential fiduciary breaches and federal securities law violations. Shareholders should stay informed.

Berger Montague Begins Investigation into Akero Therapeutics for Possible Breaches of Duty #United_States #San_Francisco #Berger_Montague #Akero_Therapeutics #Efruxifermin

Potential Legal Trouble Looms for Akero Therapeutics as Berger Montague Launches Investigation Berger Montague PC is probing Akero Therapeutics, Inc. regarding potential breaches of fiduciary duties and violations of securities laws, impacting shareholders and future mergers.

Potential Legal Trouble Looms for Akero Therapeutics as Berger Montague Launches Investigation #USA #San_Francisco #Berger_Montague #Akero_Therapeutics #Efruxifermin

Investigation Launched into Akero Therapeutics Over Board Misconduct and Securities Violations Berger Montague PC has initiated an investigation into Akero Therapeutics for potential fiduciary breaches and federal securities law violations, affecting shareholders.

Investigation Launched into Akero Therapeutics Over Board Misconduct and Securities Violations #USA #San_Francisco #Berger_Montague #Akero_Therapeutics #Efruxifermin

More #efruxifermin data this time in #MASH F2/F3 fibrosis @ 96 weeks

✅ Efficacy w/ dose dependent response (sort of) and NITs consistent
↔️ not crazy about mITT though it is mentioned no paired bx= non responders
⬇️ dose dependent reduction in bone mineral density

#liversky

MetaVia's DA-1241 and Efruxifermin Show Promising Results in Combating MASH At the ADA's 85th Scientific Sessions, MetaVia Inc. revealed that its therapy DA-1241 combined with Efruxifermin shows significant liver protection, advancing the fight against MASH.

MetaVia's DA-1241 and Efruxifermin Show Promising Results in Combating MASH #USA #Chicago #MetaVia #DA-1241 #Efruxifermin

Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SY... Among patients with baseline and week 96 biopsies, 39% of the 50mg EFX group (p=0.009) demonstrated ≥1 stage improvement in fibrosis with no worsening of...

Great news for persons w/ #MASH cirrhosis in this ph2b study of #efruxifermin
Thoughts:
🤞it is a fair statement that longer rx may yield better results but that remains to be proven
the authors are to be 👏 for presenting ITT data. MASH studies needs to move away from “completer” analyses
#liversky

96 wk #efruxifermin @akerotx
HARMONY trial:
“Paired biopsy set”
🔥 46-75% vs. 24% fibrosis improvement
ITT
🙁 30-49% vs. 20%
Up to 7 kPa ⬇️ in VCTE
No weight change
Some reduction in BMD
“Unprecedented” fibrosis improvement but not in ITT
@easlcongress @livertwitter